Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors
Despite clinical intervention, glioblastoma (GBM) remains the deadliest brain tumor in adults. Its incurability is partly related to the establishment of drug resistance, both to standard and novel treatments. In fact, even though small kinase inhibitors have changed the standard clinical practice f...
Main Authors: | Federica Fabro, Martine L. M. Lamfers, Sieger Leenstra |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/3/600 |
Similar Items
-
Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in glioblastoma
by: Federica Fabro, et al.
Published: (2022-11-01) -
Autophagy Inhibition Enhances Anti-Glioblastoma Effects of Pyrazolo[3,4-<i>d</i>]pyrimidine Tyrosine Kinase Inhibitors
by: Sofija Jovanović Stojanov, et al.
Published: (2022-09-01) -
Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment
by: Davide Frumento, et al.
Published: (2024-01-01) -
Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
by: Paula Aldaz, et al.
Published: (2021-11-01) -
Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment
by: Mahdie Rahban, et al.
Published: (2024-01-01)